Zevra director granted 30,000 stock options
Zevra Therapeutics, Inc. director Thomas Anderson received a grant of stock options covering 30,000 shares of common stock as compensation for his board service.
Rhea-AI Filing Summary
Zevra Therapeutics, Inc. director Thomas Anderson received a grant of stock options covering 30,000 shares of common stock as compensation for his board service. The options have an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026, and expire on June 3, 2036. All 30,000 options vest 100% on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Anderson Thomas
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 contracts (Direct)
Footnotes (3)
- F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
- F2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
- F3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Key Figures
Stock options granted: 30,000 options
Exercise price: $11.17 per share
Expiration date: June 3, 2036
+1 more
4 metrics
Stock options granted
30,000 options
Grant to director Thomas Anderson on June 4, 2026
Exercise price
$11.17 per share
Equal to Nasdaq closing price on June 4, 2026
Expiration date
June 3, 2036
Option term for 30,000-share grant
Post-grant derivative holdings
30,000 options
Total stock options held following this transaction
Key Terms
Stock Option (right to buy), exercise price, non-employee director compensation policy, vest, +1 more
5 terms
Stock Option (right to buy) financial
"The reporting person received a Stock Option (right to buy) covering 30,000 shares."
exercise price financial
"The exercise price is equal to the closing price on the Nasdaq Global Select Market."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
non-employee director compensation policy financial
"This grant was awarded pursuant to the issuer's non-employee director compensation policy."
vest financial
"One hundred percent of the shares subject to the option shall vest on specified dates."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
change in control financial
"Vesting may occur immediately prior to a change in control of the issuer."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
FAQ
What insider transaction did ZVRA director Thomas Anderson report?
Thomas Anderson reported receiving a grant of stock options for 30,000 shares of Zevra Therapeutics common stock. The options were awarded as compensation for his service on the board of directors under the company’s non-employee director compensation policy.
What is the exercise price of Thomas Anderson’s ZVRA stock options?
The exercise price of the stock options granted to Thomas Anderson is $11.17 per share. This price equals the closing price of Zevra Therapeutics common stock on the Nasdaq Global Select Market on the June 4, 2026 grant date.
When do Thomas Anderson’s ZVRA stock options vest?
All 30,000 options vest 100% on the earliest of three events: the first anniversary of the June 4, 2026 grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, assuming continued service.
When do Thomas Anderson’s ZVRA stock options expire?
Thomas Anderson’s stock options expire on June 3, 2036. After this expiration date, any unexercised options will lapse, meaning he would no longer have the right to buy Zevra Therapeutics common stock at the $11.17 exercise price.
Why did Zevra grant stock options to director Thomas Anderson?
Zevra granted these stock options as compensation for Thomas Anderson’s service on its board of directors. The grant was made under the company’s tenth amended and restated non-employee director compensation policy, aligning director pay with shareholder interests through equity awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
